Ligand Pharmaceuticals LGND Unrealized Gain (Loss) on Investments
Unrealized Gain (Loss) on Investments at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnInvestments.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's unrealized gain (loss) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's unrealized gain (loss) on investments?
- Ligand Pharmaceuticals (LGND) reported unrealized gain (loss) on investments of -$732K in Q1 2026.
- How has Ligand Pharmaceuticals's unrealized gain (loss) on investments changed year-over-year?
- Ligand Pharmaceuticals's unrealized gain (loss) on investments decreased by 3227.3% year-over-year, from -$22K to -$732K.
- What is the long-term trend for Ligand Pharmaceuticals's unrealized gain (loss) on investments?
- Over 2 years (2021 to 2025), Ligand Pharmaceuticals's unrealized gain (loss) on investments has grown at a -9.5% compound annual growth rate (CAGR), from -$221K to $181K.